Therapeutic potential for AFQ056, an mGluR5 antagonist, in Fragile X syndrome

A new review published July 17, 2013 in the Journal of Experimental Pharmacology
by Dr. Laurie Doering and colleagues at McMaster University in Canada

Breakthrough advances in potential therapy for FXS followed the discovery of excessive mGluR) signaling in Fragile X brain cells. Many pharmaceutical companies have designed drugs to target this defect. Promising results from animal and clinical studies suggest that mGluR5 antagonists such as AFQ056 from Novartis can successfully correct many of the deļ¬cits in Fragile X. This article covers the animal studies performed to date that test the role of AFQ056 to alleviate the phenotypes of FXS.

AFQ056, also known as mavoglurant, is being developed by Novartis for Fragile X, Parkinsons disease, and other disorders.

Read the article.